Prothena
Prothena Corporation plc is a clinical-stage biopharmaceutical enterprise headquartered in Dublin, Ireland. The company focuses on the discovery and development of novel antibody-based therapeutics designed to treat protein misfolding and neurodegenerative diseases. Its clinical pipeline targets pathological conditions including amyloidosis, Parkinson's disease, and related neurodegenerative disorders. Principal revenue is derived through research collaboration agreements, milestone payments, and pharmaceutical licensing partnerships with major healthcare enterprises. The firm supports clinical neurology research and patient care development. Prothena Corporation plc is publicly traded on the Nasdaq Stock Market.
2 of the funds FundTelligence covers report a position in Prothena.
- Legal name
- Prothena Corporation PLC
- Sector
- Health Care
- Country
- Ireland
- Funds holding it
- 2
- Exposure themes
- Ageing & Longevity, Age-Related Disease, Neurodegeneration
Funds holding Prothena
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.03 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.03 % (full portfolio disclosed, October 2026)